FDA Panel Addresses Potential COVID-19 Vaccine Concerns
An FDA advisory panel convened for the first time Thursday to discuss requirements and guidance surrounding any potential coronavirus vaccine. NBC's Sarah Dallof reports.
(NBC News) — An FDA advisory panel convened for the first time Thursday to discuss requirements and guidance surrounding any potential coronavirus vaccine.
The meeting was streamed online via YouTube, an unusual move that could help reassure a nervous public vaccine approvals will be driven by science, not politics.
“You can have a fantastic vaccine, but if no one takes it it’s not going to do much to end this pandemic,” says Dr. Hilary Marston of the National Institutes of Health.
It comes as Moderna, the first company to start clinical trials in the U.S., announced it’s enrolled all 30,000 of its participants.
Moderna’s vaccine is one of four in critical stage three trials in the country, although two, manufactured by Aztrazenca and Johnson and Johnson, remain on hold after a participant in each fell ill.
According to a recent survey published in online medical journal “JAMA,” Americans are more likely to get a vaccine if it has full FDA approval instead of emergency use authorization, as well as higher efficacy, fewer side effects and endorsements from the Centers for Disease Control and World Health Organization.
Read more here.